The short version of fatty diacid fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-08. Anything still debated is marked as such rather than presented as settled.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Unmodified peptide backbone |
| Molecular mass | approx. 4,813 Da | 39-residue linear chain |
| Receptor targets | GIP and GLP-1 | Dual agonist activity |
| Route | Subcutaneous injection | Weekly administration interval |
| Elimination half-life | approx. 5 days | Supports weekly dosing schedule |
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
Purified material is typically handled as a lyophilized powder kept at or below minus twenty degrees Celsius, shielded from light and moisture. In that state the solid remains stable for extended periods, although repeated freeze-thaw cycling can encourage aggregation. Once dissolved, aqueous solutions are less durable and are generally held cold and used within a brief window. Buffer composition, pH and ionic strength all influence degradation rates, and mildly acidic to neutral conditions are commonly examined. Actual shelf life depends on formulation, concentration and container, so stability limits are established experimentally rather than assumed.
Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
Identity and purity of tirzepatide are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Because the molecule carries several modifications, gradient conditions are adjusted to resolve the intact peptide from deamidation and oxidation products. Enzymatic digestion followed by peptide mapping confirms the primary sequence and locates specific modifications. Quantitation in biological matrices typically uses liquid chromatography with tandem mass spectrometry after solid-phase extraction. Immunoassays are used less often, since antibody cross-reactivity with closely related peptides can bias results.
The peptide shares degradation routes common to modified peptides: deamidation of asparagine and glutamine residues, oxidation of methionine, and backbone hydrolysis under extreme pH. Lyophilized material is generally more stable than a solution, and residual water content directly affects the rate of hydrolysis. In liquid form, aggregation and visible particles can appear after agitation or repeated freeze-thaw cycles. Stability studies therefore track monomer content, aggregate content, and potency over months under defined temperature and humidity.
Cold-chain handling is standard for formulated product, with dry powder stored frozen and ready-to-use solutions refrigerated. Light exposure is minimized because photodegradation of certain amino acid side chains is possible. Shipping and temperature-excursion studies are used to establish whether short deviations affect quality attributes. Documentation supplied with research material usually includes a certificate of analysis listing purity, identity confirmation, and water or residual solvent content. Users are expected to confirm that material meets the stated specification before use.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Nihonium is the first member of the 7p series of elements and the heaviest group 13 element on the periodic table, below boron, aluminium, gallium, indium, and thallium. All the group 13 elements except boron are metals, and nihonium is expected to follow suit. Nihonium is predicted to show many differences from its lighter homologues. The major reason for this is the spin–orbit (SO) interaction, which is especially strong for the superheavy elements, because their electrons move much faster than in lighter atoms, at velocities close to the speed of light. In relation to nihonium atoms, it lowers the 7s and the 7p electron energy levels (stabilising those electrons), but two of the 7p electron energy levels are stabilised more than the other four. The stabilisation of the 7s electrons is called the inert pair effect, and the separation of the 7p subshell into the more and less stabilised parts is called subshell splitting. Computational chemists see the split as a change of the second, azimuthal quantum number l, from 1 to 1/2 and 3/2 for the more and less stabilised parts of the 7p subshell, respectively. The quantum number corresponds to the letter in the electron orbital name: 0 to s, 1 to p, 2 to d, etc. For theoretical purposes, the valence electron configuration may be represented to reflect the 7p subshell split as 7s2 7p1/21. The first ionisation energy of nihonium is expected to be 7.306 eV, the highest among the metals of group 13. Similar subshell splitting should exist for the 6d electron levels, with four being 6d3/2 and six being 6d5/2.
Myomeres are overlapping "cones" of muscle fibers bound by connective tissue. The shape of myomeres varies by species. Myomeres are commonly zig-zaged, being stacks or lines of muscle fibers shaped like "V" (lancelets), "W" (fishes), or straight (tetrapods). Generally, cyclostome myomeres are arranged in vertical strips while those of jawed fishes are folded in a complex manner due to their derived nature and evolution of advanced swimming capability. Specifically, myomeres of elasmobranchs and eels are W-shaped, while the myomeres of tetrapods, such as mudpuppies, run vertically and do not display complex folding. Myomeres overlap each other in succession, meaning myomere activation also allows neighboring myomeres to activate. They are innervated by spinal nerves, which pass into each myomere. Myomeres are made up of myoglobin-rich dark muscle as well as white muscle. Dark muscles generally function as slow-twitch muscle fibers while white muscle is composed of fast-twitch fibers. In gnathostomes, the myomeres are separated by myoseptal tendons. Specifically, these are the myorhabdoid tendons, the lateral tendons, the epineural tendon, and the epipleural tendon.
Therefore, hyperhomocysteinemia is a possible risk factor for coronary artery disease. Coronary artery disease occurs when an atherosclerotic plaque blocks blood flow to the coronary arteries, which supply the heart with oxygenated blood. Hyperhomocysteinemia has also been correlated with the occurrence of blood clots, heart attacks, and strokes, although it is unclear whether hyperhomocysteinemia is an independent risk factor for these conditions. Hyperhomocysteinemia has also been associated with early-term spontaneous abortions and with neural tube defects.
Sources: en.wikipedia.org
Anger over the treatment of demonstrators following the death of Benno Ohnesorg and the attack on Rudi Dutschke, coupled with growing frustration over the lack of success in achieving their aims led to growing militance among students and their supporters. In May 1968, three young people set fire to two department stores in Frankfurt; they were brought to trial and made clear to the court that they regarded their action as a legitimate act in what they described as the "struggle against imperialism". The student movement began to split into different factions, ranging from the unattached liberals to the Maoists and supporters of direct action in every form—the anarchists. Several groups set as their objective the aim of radicalising the industrial workers; taking an example from activities in Italy of the Red Brigades (Brigate Rosse), many students went to work in the factories, but with little or no success. The most notorious of the underground groups was the Red Army Faction, which began by making bank raids to finance their activities and eventually went underground having killed a number of policemen, several bystanders and eventually two prominent West Germans, whom they had taken captive in order to force the release of prisoners sympathetic to their ideas. In the 1990s, attacks were still being committed under the name "RAF". The last action took place in 1993 and the group announced it was giving up its activities in 1998.
==== MeSH D12.776.664.235.400 – high mobility group proteins ==== MeSH D12.776.664.235.400.400 – hmgn proteins MeSH D12.776.664.235.400.400.200 – hmgn1 protein MeSH D12.776.664.235.400.400.300 – hmgn2 protein MeSH D12.776.664.235.400.500 – hmga proteins MeSH D12.776.664.235.400.500.100 – hmga1a protein MeSH D12.776.664.235.400.500.200 – hmga1b protein MeSH D12.776.664.235.400.500.300 – hmga1c protein MeSH D12.776.664.235.400.500.600 – hmga2 protein MeSH D12.776.664.235.400.600 – hmgb proteins MeSH D12.776.664.235.400.600.300 – hmgb1 protein MeSH D12.776.664.235.400.600.600 – hmgb2 protein MeSH D12.776.664.235.400.600.800 – hmgb3 protein MeSH D12.776.664.235.400.700 – sex-determining region y protein MeSH D12.776.664.235.400.800 – tcf transcription factors MeSH D12.776.664.235.400.800.500 – lymphoid enhancer-binding factor 1 MeSH D12.776.664.235.400.800.750 – t cell transcription factor 1
Fentanyl acts on opioid receptors. These receptors are G-protein-coupled receptors, which contain seven transmembrane portions, intracellular loops, extracellular loops, intracellular C-terminus, and extracellular N-terminus. The extracellular N-terminus is important in differentiating different types of binding substrates. When fentanyl binds, downstream signaling leads to inhibitory effects, such as decreased cAMP production, decreased calcium ion influx, and increased potassium efflux. This inhibits the ascending pathways in the central nervous system to increase pain threshold by changing the perception of pain; this is mediated by decreasing propagation of nociceptive signals, resulting in analgesic effects. The affinity of fentanyl to the μ-opioid receptor is similar to that of morphine. The reasons for fentanyl's increased potency in vivo are unclear, however differences in efficacy and pharmacokinetics may be involved. It has high lipid solubility, allowing it to penetrate more easily the central nervous system. It attenuates "second pain" with primary effects on slow-conducting, unmyelinated C-fibers and is less effective on neuropathic pain and "first pain" signals through small, myelinated A-fibers. Fentanyl can produce the following clinical effects strongly, through μ-receptor agonism:
Sources: en.wikipedia.org
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.
Selective agents engage only the GLP-1 receptor, whereas tirzepatide activates GIP and GLP-1 receptors simultaneously. This difference in receptor coverage is the principal pharmacological distinction emphasised in comparative reviews.
Downstream signalling is partly characterised, but the quantitative contribution of GIP versus GLP-1 receptor activation to metabolic outcomes is not settled. Review articles commonly flag this as an unresolved question rather than a settled finding.
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.